Details

Autor(en) / Beteiligte

• Roden, Dan M
• Wood, Alastair J.J.

Titel

Drug-Induced Prolongation of the QT Interval

Ist Teil von

• The New England journal of medicine, 2004-03, Vol.350 (10), p.1013-1022

Ort / Verlag

Boston, MA: Massachusetts Medical Society

Erscheinungsjahr

2004

Link zum Volltext

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• The single most common cause of the withdrawal or restriction of the use of marketed drugs has been QT-interval prolongation associated with polymorphic ventricular tachycardia, or torsade de pointes, a condition that can be fatal. This review summarizes the current knowledge about molecular and clinical predictors of drug-induced QT-interval prolongation and torsade de pointes and discusses how new molecular predictors of drug action might be incorporated into drug-development programs and clinical practice. A general approach to drugs suspected of causing this problem is presented. In the past decade, the single most common cause of the withdrawal or restriction of the use of drugs that have already been marketed has been the prolongation of the QT interval associated with polymorphic ventricular tachycardia, or torsade de pointes (Figure 1), which can be fatal. 1 Nine structurally unrelated drugs that were marketed in the United States or elsewhere for a range of noncardiovascular indications have been removed from the market or had their availability severely restricted because of this rare form of toxicity. These drugs are terfenadine, astemizole, grepafloxicin, terodiline, droperidol, lidoflazine, sertindole, levomethadyl, and cisapride. A convergence . . .